MicroRNA miR-509-3p inhibit metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117.
   PubMed Web of Science ®Google Scholar
• Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141:196–202.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res. 2013;43:147–154.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2006;22(3):248–253.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen L. Tumor microenviroment and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol. 2013;28(Suppl 1):43–48.
   PubMedGoogle Scholar
• Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233–1247.
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658.
   PubMed Web of Science ®Google Scholar
• Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57:840–847.
   PubMed Web of Science ®Google Scholar
• Yang H, Fang F, Chang R, et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013;58:205–217.
   PubMed Web of Science ®Google Scholar
• Fang F, Chang RM, Yu L, et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63:874–885.
   PubMed Web of Science ®Google Scholar
• Chang RM, Yang H, Fang F, et al. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60:1251–1263.
   PubMed Web of Science ®Google Scholar
• Chen W, Du J, Li X, et al. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics. 2017;18:1671–1682.
   PubMed Web of Science ®Google Scholar
• Du P, Luan X, Liao Y, et al. MicroRNA-509-3p inhibits cell proliferation and invasion via downregulation of X-linked inhibitor of apoptosis in glioma. Oncol Lett. 2018;15:1307–1312.
   PubMed Web of Science ®Google Scholar
• Pan Y, Robertson G, Pedersen L, et al. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2017;8:17406.
   PubMedGoogle Scholar
• Patil SL, Palat A, Pan Y, et al. MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep. 2019;9:19089.
   PubMed Web of Science ®Google Scholar
• Li W, He Y, Chen W, et al. Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis. Gene Ther. 2020. DOI:10.1038/s41434-020-0137-9
   Web of Science ®Google Scholar
• Yuan R, Wang K, Hu J, et al. Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation. Cancer Res. 2014;74:5287–5300.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469.
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
   PubMed Web of Science ®Google Scholar
• Lu Y, Yue X, Cui Y, et al. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 2013;441:873–879.
   PubMed Web of Science ®Google Scholar
• Hua S, Liu C, Liu L, et al. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. Biochem Biophys Res Commun. 2018;496:947–954.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Gong HY, Tseng HC, et al. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008;375:315–320.
   PubMed Web of Science ®Google Scholar
• Sun T, Sun BC, Zhao XL, et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology. 2011;54:1690–1706.
   PubMed Web of Science ®Google Scholar
• Vesuna F, Van Diest P, Chen JH, et al. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235–241.
   PubMed Web of Science ®Google Scholar
• Kim J, Bae S, An S, et al. Cooperative actions of p21WAF1 and p53 induce Slug protein degradation and suppress cell invasion. EMBO Rep. 2014;15:1062–1068.
   PubMed Web of Science ®Google Scholar
• Wallerand H, Robert G, Pasticier G, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 2010;28:473–479.
   PubMed Web of Science ®Google Scholar
• Grzegrzolka J, Biala M, Wojtyra P, et al. Expression of EMT markers SLUG and TWIST in breast cancer. Anticancer Res. 2015;35:3961–3968.
   PubMed Web of Science ®Google Scholar
• Meng J, Chen S, Han JX, et al. Twist1 regulates vimentin through Cul2 circular RNA to Promote EMT in hepatocellular carcinoma. Cancer Res. 2018;78:4150–4162.
   PubMed Web of Science ®Google Scholar